+33 (0)251 252 000 contact@inflectisbioscience.com

ISR Modulators

InFlectis is developing a family of small molecules to modulate eIF2α, the ISR’s biomolecular switch. When this switch is turned on, by phosphorylation of eIF2α, cells are able to respond to protein imbalances to reduce harmful levels of defective proteins.

InFlectis’ small molecules selectively target a phosphatase complex, PPP1R15A/PP1c. So long as PPP1R15A/PP1c is inhibited, the biomolecular switch – the phosphorylated eIF2α – remains turned on, prolonging the natural benefit of the ISR and giving cells additional time to correct protein imbalances and repair or eliminate misfolded proteins.

Preclinical research has repeatedly and consistently shown the ability of PPP1R15A inhibitors to prolong ISR activity in defective cells and prevent cytotoxicity. Further, preclinical and clinical research has shown promise in treating neuromuscular diseases, through remyelination in patients with CMT and MS, and motor function improvement in ALS patients. This includes demonstrating remyelination, which holds promise for treating neuromuscular diseases, through remyelination in people living with CMT and MS, and motor function improvement in people living with ALS.

Sephin Yellow